149 related articles for article (PubMed ID: 24048635)
1. Sudden blindness due to bilateral central retinal artery occlusion in a patient on eltrombopag.
Au WY; Ma ES; Chow PC; Kan YT
Ann Hematol; 2014 May; 93(5):881-2. PubMed ID: 24048635
[No Abstract] [Full Text] [Related]
2. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
3. Extensive cerebral venous sinus thrombosis following a dose increase in eltrombopag in a patient with idiopathic thrombocytopenic purpura.
Mulla CM; Rashidi A; Levitov AB
Platelets; 2014; 25(2):144-6. PubMed ID: 23320857
[No Abstract] [Full Text] [Related]
4. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
Depré F; Aboud N; Mayer B; Salama A
Blood Transfus; 2018 May; 16(3):307-312. PubMed ID: 28151387
[TBL] [Abstract][Full Text] [Related]
5. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag named patient programme for patients with chronic immune thrombocytopenia.
Scully M; Kaczmarski R; Myers B; Collins R; Emohare O; Bolton-Maggs PH
Br J Haematol; 2012 Apr; 157(2):259-60. PubMed ID: 22091659
[No Abstract] [Full Text] [Related]
7. Eltrombopag for chronic immune thrombocytopenia.
Tanimoto T; Fukunaga S; Hori A; Yagasaki F; Ono S
Lancet; 2011 Jun; 377(9781):1919; author reply 1919-20. PubMed ID: 21641478
[No Abstract] [Full Text] [Related]
8. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
9. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
Kowalczyk M; Rubinstein PG; Aboulafia DM
J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag in systemic lupus erythematosus with antiphospholipid syndrome: thrombotic events.
Boulon C; Vircoulon M; Constans J
Lupus; 2016 Mar; 25(3):331. PubMed ID: 26405023
[No Abstract] [Full Text] [Related]
11. Two new drugs for chronic ITP.
Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
[TBL] [Abstract][Full Text] [Related]
12. Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study.
Meyer O; Wong RSM; Khelif A; Stankovic M; Maier J; Saleh MN; Bussel JB
Br J Haematol; 2022 Jan; 196(2):448-452. PubMed ID: 34458977
[No Abstract] [Full Text] [Related]
13. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.
Brynes RK; Orazi A; Theodore D; Burgess P; Bailey CK; Thein MM; Bakshi KK
Am J Hematol; 2015 Jul; 90(7):598-601. PubMed ID: 25801698
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag.
Garnock-Jones KP; Keam SJ
Drugs; 2009; 69(5):567-76. PubMed ID: 19368418
[TBL] [Abstract][Full Text] [Related]
15. Sustaining platelet counts in chronic ITP.
Nurden AT
Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056
[No Abstract] [Full Text] [Related]
16. Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin receptor agonist.
Simpson JD; Matthews GV; Brighton TA; Joseph JE
Intern Med J; 2016 Sep; 46(9):1096-9. PubMed ID: 27633469
[TBL] [Abstract][Full Text] [Related]
17. Molecule of the month. Eltrombopag.
Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
[No Abstract] [Full Text] [Related]
18. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.
Saleh MN; Bussel JB; Cheng G; Meyer O; Bailey CK; Arning M; Brainsky A;
Blood; 2013 Jan; 121(3):537-45. PubMed ID: 23169778
[TBL] [Abstract][Full Text] [Related]
19. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Ghanima W; Junker P; Hasselbalch HC; Boiocchi L; Geyer JT; Feng X; Gudbrandsdottir S; Orazi A; Bussel JB
Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
[TBL] [Abstract][Full Text] [Related]
20. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
[Next] [New Search]
